Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24781748 | 0.82 | HSP90AA1 (0.40) | BUB1HSP90AA1HSP90AB1BCHEPIK3R1 | |
| SCHEMBL24781749 | 0.81 | BCHE (0.40) | BUB1HSP90AA1HSP90AB1BCHEPIK3R1 | |
| SCHEMBL24781753 | 0.80 | HSP90AA1 (0.39) | BUB1HSP90AA1HSP90AB1BCHEPIK3R1 | |
| SCHEMBL16018700 | 0.76 | BUB1 (0.38) | BUB1HSP90AA1HSP90AB1BCHEPIK3R1 | |
| SCHEMBL15412342 | 0.75 | USP30 (0.40) | BUB1USP30BCHEAAK1PRMT5 | |
| SCHEMBL30606423 | 0.75 | BRD4 (0.39) | BUB1USP30BCHEAAK1PRMT5 | |
| SCHEMBL715654 | 0.75 | BRD4 (0.39) | BUB1USP30BCHEAAK1PRMT5 | |
| SCHEMBL24053343 | 0.73 | USP30 (0.35) | BUB1USP30AAK1PRMT5WDR77 | |
| SCHEMBL616604 | 0.73 | NR1H2 (0.48) | — | |
| SCHEMBL29698752 | 0.73 | L3MBTL1 (0.49) | BUB1USP30BCHEL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709712-A1 | GSK3A INHIBITORS AND METHODS OF USE THEREOF | Blueprint Medicines Corporation (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12454529-B2 | Piperazine cyclic ureas | Sironax Ltd. (KY) | 2025-10-28 | — | — | US | disclosed |
| WO-2025090541-A1 | COVALENT DEGRADERS OF ONCOGENIC TRANSCRIPTION FACTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2024233900-A1 | GSK3A INHIBITORS AND METHODS OF USE THEREOF | BLUEPRINT MEDICINES CORPORATION (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-118359608-A | METTL3 inhibitor compounds and uses thereof | 成都先导药物开发股份有限公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20230203019-A1 | Piperazine Cyclic Ureas | SIRONAX (BEIJING) CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203019-A1 | Piperazine Cyclic Ureas | SIRONAX (BEIJING) CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| CN-115697991-A | Piperazine cyclic ureas | 维泰瑞隆有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2022249992-A1 | PRODUCTION METHOD FOR BIPYRIDINE DERIVATIVE, PRODUCTION METHOD FOR MACROCYCLIC COMPOUND, PRODUCTION METHOD FOR METAL COMPLEX INCLUDING MACROCYCLIC COMPOUND AS LIGAND, METAL COMPLEX, ELECTRODE FOR AIR BATTERY, AND AIR BATTERY | 住友化学株式会社 | 2022-12-01 | — | — | WO | disclosed |
| EP-2978761-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AS CETP INHIBITOR, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Dong-A ST Co., Ltd. (KR) | 2016-02-03 | — | — | EP | disclosed |
| US-9149465-B2 | Isoxazolines as inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150126485-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| EP-2861576-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | Novartis AG (CH) | 2015-04-22 | — | — | EP | disclosed |
| WO-2014209978-A1 | IMIDAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014157994-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AS CETP INHIBITOR, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG-A ST CO.,LTD (KR) | 2014-10-02 | — | — | WO | disclosed |
| WO-2013171642-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2013-11-21 | — | — | WO | disclosed |
| EP-2432771-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Infinity Pharmaceuticals, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20110028478-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| WO-2010135360-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028478-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, HRH2 | BUB1 4829/4885HSP90AA1 1946/4885HSP90AB1 2002/4885 |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, GDI2 | BUB1 1483/4885HSP90AA1 1257/4885HSP90AB1 768/4885 |
| US-12454529-B2 | Piperazine cyclic ureas | RIPK1, RIPK3, RIPK4 | BUB1 463/4885HSP90AA1 1206/4885HSP90AB1 1254/4885 |
| US-20230203019-A1 | Piperazine Cyclic Ureas | RIPK1, RIPK3, RIPK4 | BUB1 463/4885HSP90AA1 1206/4885HSP90AB1 1254/4885 |
| US-20150126485-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | ABL1, ABL2, BCR | BUB1 2241/4885HSP90AA1 1538/4885HSP90AB1 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.